Malaysia Ministry of Health Launching 500 Patient Ivermectin Trial at 10 Public Hospitals Investigating Efficacy for Critical COVID-19 Patients
Ivermectin Not Accepted Off Label In Malaysia,
the General Director of Health
Dr. Noor Hisham Abdullah recently declared for Malaysian media:The FDA has not approved Ivermectin for use in treating or preventing Covid-19 in humans,
and
the World Health Organization (WHO) only recommends the use of Ivermectin in a clinical trial setting, in which patients are monitored closely by experienced clinicians and researchers for safety and efficacy.
Dr. Noor Hisham Abdullah recently issued a formal statement emphasizing that
there isn’t any conclusive proof for ivermectin as an agent for COVID-19
declaring
The Ministry of Health Malaysia
has initiated a randomized clinical trial to repurpose Ivermectin and evaluate its efficacy and safety in high risk COVID-19 patients (NMRR-21-155-58433).
The trial will enroll 500 COVID-19 patients admitted to 12 MOH hospitals.
Through this study,
MOH hopes to have a correct perspective on the clinical effectiveness of Ivermectin.
Although Malaysia’s risk for COVID-19 may be heightened at the moment,
we must keep in mind that in all circumstances, we need to take steps necessary to figure out what really works.
Without the benefit of evidence from well-designed clinical trials,
the Ministry of Health Malaysia is not yet able to endorse Ivermectin to prevent or treat COVID-19 illness.
Science remains the best weapon against the SARS-Cov-2 virus, not circumstantial hype.